Hubert Chaperon

AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate San Francisco-based biotech AltruBio has raised $225 million in an oversubscribed Series B round, the company announced Tuesday. The financing will help the company advance its ulcerative colitis candidate into mid-stage clinical trials. AltruBio’s candidate ALTB-268 is a first-in-class immune checkpoint enhancer (ICE) PSGL agonist antibody that is currently in a Phase IIa exploratory biomarker study in patients with biologic refractory ulcerative colitis (UC). The readout for the Phase IIa’s primary endpoint of clinical remission per modified Mayo score is expected sometime in the first half of next year. The Series B funds will support the trial and a Phase IIb study, which will have a primary endpoint of clinical remission in advanced therapy experienced and treatment naïve patients with moderate to severe UC. The biotech expects a readout in the second half of 2026. The Phase I data for ALTB-268 was encouraging as AltruBio reported positive topline data in August 2023. While the company initially gave no hard data points, the data supported the candidate’s progression into Phase II studies. “With this substantial investment, we are one step closer to bringing our first-in-class, novel immune checkpoint enhancer, ALTB-268, through our ongoing Phase IIa exploratory biomarker study and initiating an additional Phase IIb study while paving the way for potential indication expansion beyond ulcerative colitis,” AltruBio CEO Judy Chou said in a statement. https://lnkd.in/earF9qf7

13

Committed to enabling you to #discovermore and #developfaster, we've released a new tool to support your discovery efforts: our searchable 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐀𝐬𝐬𝐚𝐲 𝐌𝐞𝐧𝐮: https://bit.ly/4cxI5tL How can you best use this interactive menu? 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 #𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐚𝐧𝐝 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐓𝐚𝐫𝐠𝐞𝐭𝐬 Peruse the full breadth of 12,000+ proteins and post-translational modifications (PTMs) we measure with our nontargeted #proteomics methods in your sample matrix of choice (plasma, cells, or tissue). See the coverage depth we can offer to assess proteome perturbations caused by disease processes or #drugresponse, and to profile differentially expressed proteins that may represent therapeutic targets. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐀𝐬𝐬𝐚𝐲 𝐘𝐨𝐮𝐫 𝐏𝐫𝐨𝐭𝐞𝐢𝐧(𝐬) 𝐨𝐟 𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭 If you have a specific protein to interrogate or target you're looking to modulate, you can easily search for it by name, UniProtID, or gene symbol. You can also filter the list for proteins associated with signaling pathways, biological processes, and a range of phenotypes to find those of relevance to probe for your study. Easily request these off-the-shelf, quantitative assays using the embedded forms. Get started here: https://bit.ly/4cxI5tL and don't hesitate to reach out to me if you have questions.

3

Learn how to use spectroscopy in your processes! See how you can reduce the complexity of the calibration and how PAT can be integrated into your single-use processes! #PAT #bioprocessing #DSP #USP #spectroscopy

6

Very Proud of Progenesis team. After hard work and group effort, It is my pleasure to announce the official launch of our High-Resolution Translocation Test. This is a single base resolution test that can distinguish between euploid and balanced translocation and detect small translocations (under 1MB) currently rejected with conventional PGT-SR. With this test, patients will increase their chance of having a successful pregnancy and reduce the risk of passing balance translocation and infertility to their kids. We are also launching Previda-Plus a test that can detect Triploidy, Haploidy, and Maternity/Paternity of embryos. This test will increase usability of 1pn, 3pn embryos and serve as a witness step for embryo transfer. #ivf #ivfjourney #infertility #ivfsuccess #ivfwarrior #ttccommunity #ivfcommunity #ttc #fertility #infertilityjourney #ivftransfer #ivftreatment #ivfstory #embryo #embryology #ttcsupport #reproductivehealth #fertility #infertility #pregnancy #fertilization Progenesis BrasilProgenesis India

92

8 commentaires

What's driving all the recent excitement and investment in peptide macrocycles? Have a look at this article by C&EN featuring Menten AI and co-founder Vikram K. Mulligan on the disruptive potential of peptide macrocycles. #aidrugdiscovery #peptides #AI #biotech #genAI

30

In drug development, relying on outdated models can lead to missed opportunities for innovation and progress. A prime example is the continued use of Caco-2 cells for assessing intestinal absorption. While they have been a long-standing tool in the industry, it's time to recognize their limitations and explore more advanced alternatives. Here are three key reasons why Caco-2 cells fall short and why we should consider better options for more accurate and predictive results. 𝟭. 𝗟𝗮𝗰𝗸 𝗼𝗳 𝗖𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆: Caco-2 cells originate from a single cell line, representing only one aspect of the intestinal epithelium. They lack the diversity and complexity of the human intestinal barrier, including the presence of various cell types such as goblet cells, enteroendocrine cells, and immune cells. This oversimplification can lead to inaccurate predictions of drug absorption and metabolism. 𝟮. 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀 𝗶𝗻 𝗘𝘅𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗟𝗲𝘃𝗲𝗹𝘀: Caco-2 cells often exhibit different levels of transporters and enzymes compared to human intestines. This disparity can lead to incorrect predictions of drug permeability and interaction with transport proteins, potentially resulting in inaccurate assessment of a drug's bioavailability and pharmacokinetics. 𝟯. 𝗟𝗶𝗺𝗶𝘁𝗲𝗱 𝗣𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗥𝗲𝗹𝗲𝘃𝗮𝗻𝗰𝗲: Caco-2 cells do not accurately mimic the full range of physiological conditions present in the human gut, such as pH variations, enzyme activity, and interactions with gut microbiota. This limitation can result in an incomplete understanding of how a drug behaves in the gastrointestinal tract. By moving beyond the status quo and embracing these advanced models, researchers can achieve more accurate and predictive results in drug development, ultimately leading to more effective and safer therapeutics.

12

1 commentaire

Windfall Bio has secured $28m in Series A funding to further develop its methane-eating microbial. This investment from Amazon, B37 Ventures, and other partners is a testament to the company's vision of creating a more sustainable world. Who doubts that the Biocontrol market is not growing, especially microbial marbles for biofertilizers? Microbials can fix atmospheric nitrogen from 30-50kg Microbials can solubilise nutrients and make them ready for plants. Microbials can eat methane contributing towards CO2 reduction. Microbials can form a layer around the plant as Biofilm protecting roots and increasing resilience This investment shows the power of microbes Josh Silverman. Time is not far when these microbes can form a bigger part of fertiliser inputs and reduce their use in agriculture, making the soil more healthy. https://lnkd.in/dAhwQhqX

19

3 commentaires

🚨 Breaking news 🚨 iktos acquires SYNSIGHT, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery. As Yann Gaston-Mathe, CEO and Co-founder of Iktos comments « The acquisition of Synsight enables Iktos to expand its platform to new modulators of Protein-Protein interaction’s and RNA-Protein Interaction’s, historically highly challenging targets, thereby addressing major unmet medical needs in various therapeutic areas such as cancer and neurodegenerative diseases » The merger further complements Iktos' AI-based drug discovery platform, that currently includes generative AI design, Retrosynthesis, and AI-driven automated synthesis capabilities by adding the key step of automated biological testing thanks to MT Bench technology originally developed at INSERM. 👉 To learn more about this acquisition: https://lnkd.in/ez7hHmM8 #drugdiscovery #artificialintelligence #proteinproteininteractions #RNAinteractions Genopole Medicen Paris Region

157

7 commentaires

A very nice application of #software to improve productivity in #chromatography #massspectrometry workflows by Mestrelab Research S.L. , part of the SciY family, with an excellent ROI as proven already by early adopter use cases #labautomation #laboratoryautomation #drugdiscovery #drugdevelopment

12

🚀 Big News in Biopharma! 🚀 Profluent is making waves at the intersection of biotech and AI. Their innovative approach promises to revolutionize gene editing, and they're doing it with a bold move: open-sourcing their work! 🌐🔬 Introducing OpenCRISPR 🧬 Profluent's OpenCRISPR initiative is set to provide customizable gene-editing proteins designed entirely by AI. Imagine AI-generated CRISPR-like proteins that have never been seen before, capable of editing the human genome with unparalleled precision. 🔍 Highlights: AI-Powered: Trained on vast databases of protein sequences, Profluent's AI can generate hundreds of thousands of CRISPR-like proteins. OpenCRISPR-1: Their top-performing AI-created gene editor boasts 400+ mutations compared to CRISPR-Cas9, reducing off-target editing by 95% and keeping unwanted genetic changes below 1%. Why This Matters Attempting to edit human DNA with AI-designed systems is nothing short of a scientific moonshot. Profluent's success points to a future where AI can design bespoke cures for diseases, democratizing gene editing. 🔬 Real-World Impact: While AI-designed drugs have been in clinical testing for years, CRISPR tech just got its FDA green light last year with Casgevy for sickle cell disease and beta thalassemia. These treatments show the incredible potential of gene editing to transform lives. Open Collaboration Profluent invites researchers to test and provide feedback on OpenCRISPR-1. Their goal is to partner with top research institutions and drug developers to expedite the development of new genetic therapies, ensuring safe and ethical practices. Recent Milestones $35M Funding: Backed by Spark Capital, Insight Partners, Air Street Capital, and top angel investors from OpenAI, Salesforce, and Google. Join the Revolution This is a watershed moment in gene editing. Profluent is not just pushing the boundaries of what's possible; they’re opening the doors for global collaboration. Let's build the next generation of genetic medicines together! 👉 Read more and get involved: https://lnkd.in/gN9p-H6j #GeneEditing #CRISPR #AI #Biotech #OpenSource #Innovation #Profluent #HealthcareRevolution

18

🌟 Reminder: Micro Scale-Down Webinar! 🌟 Discover how to efficiently scale down your freeze-thaw system using less than 10mL of biological material!

8

Vinod Khosla, founder of Sun Microsystems and Khosla Ventures “It’s better to try and fail, than fail to try”. Many times we are asked about the challenges of innovating in biotech from Patagonia and why we do it. There are many advantages of being in a place were talent wants to live, but beyond that, we know that turning Patagonia into a biotech powerhouse, can structurally change the society and living standards of our region. When so much good can be created, we rather try and fail, than fail to try. Kura Biotech Blikka Genomics by Kura Biotech SynBioBeta #PatagoniaBiotechHUB

22

Epoch 17: BIOTECH PIPES 👉 Investors favor public over private investing? 👉 Why PIPEs have come into favor? 👉 Just how much are PIPEs outperforming? 👉 What is all the controversy about? https://lnkd.in/dEkBy2bY

1

🎉 Feedvax powers growth with annual distribution offerings of over $20 million! 🚀 At Feedvax, we are on a mission to revolutionize animal health and we are excited to share a milestone that validates our vision and technology. We recently closed a second distribution agreement, securing purchase commitments worth more than $20 million annually. 🤝💼 What does this mean? It is a huge vote of confidence in our innovative oral vaccine platform that is transforming the way farmers manage animal health. By eliminating the need for stressful animal handling we are unlocking unprecedented efficiency and welfare gains. And with these partnerships, we are poised to accelerate our global impact and market leadership. 🌍🥇 For our investors, this is an exciting validation of Feedvax's tremendous growth potential as we continue to expand our footprint reducing the $300 billion losses in the animal health industry due to diseases. 📈🔬 Thanks to all the FeedVax team, investors, and the people who support our growth every day. The future of animal health is simple, without stress  and powered by Feedvax. 🚀 #Feedvax #AgTech #Sustainability #AnimalHealth #theendofanimalhandling

51

8 commentaires

Price + Performance = Success Learn more next Wednesday at 10am ET!

4

Did you know that the Poisson distribution in droplet technology is your friend? Read this and learn about the advantages of having "build-in" controls in your experiments.

15